Table 1.
Studies on corticosteroid therapy for COVID-19
| Reference | Patients | Location | Types of study | Period | CS used for all | CFR | Corticosteroid |
CFR |
||
|---|---|---|---|---|---|---|---|---|---|---|
| Severe | Non-severe | CS | Non-CS | |||||||
| Huang et al. [2] | 41 | Wuhan, Jinyintan Hospital | SCR | inception to 2/1/2020 | 9/41 | 6/41 | 6/13 | 3/28 | 4/9 | 2/32 |
| Chen et al. [35] | 99 | Wuhan, Jinyintan Hospital | SCR | 1/1/2020 to 20/1/2020 | 19/99 | 11/99 | 11/23 | 8/76 | 6/19 | 5/80 |
| Zhou et al. [42] | 15 | Wuhan | SCR | 1/1/2020 to 29/1/2020 | 15/15 | 7/15 | 15/15 | NA | 7/15 | NA |
| Wang et al. [36] | 138 | Wuhan, Zhongnan Hospital | SCR | 1/1/2020 to 3/2/2020 | 72/138 | 6/138 | 26/36 | 36/102 | 4/62 | 2/76 |
| Xu et al. [37] | 62 | Zhejiang | MCR | 10/1/2020 to 26/1/2020 | 16/62 | 1/62 | 1/1 | 15/61 | 1/16 | 0/46 |
| Guan et al. [38] | 1099 | China | MCR | inception to 29/1/2020 | 204/1099 | 15/1099 | 77/173 | 127/926 | 6/204 | 9/895 |
| Yang et al. [41] | 52 | Wuhan, Jinyintan Hospital | SCR | late Dec 2019 to 9/2/2020 | 30/52 | 32/52 | 30/52 | NA | 16/30 | 16/22 |
| Yang et al. [39] | 149 | Wenzhou | MCR | 17/1/2020 to 15/2/2020 | 5/149 | 0/149 | NA | NA | NA | NA |
| Wu et al. [40] | 80 | Jiangsu | MCR | 22/1/2020 to 14/2/2020 | 12/80 | 0/80 | NA | NA | NA | NA |
| Li et al. [44] | 225 | Hanchuan City People's Hospital | SCR | 20/1/2020 to 14/2/2020 | 100/225 | 2/225 | NA | NA | NA | NA |
| Wang et al. [43] | 46 | Union Hospital of Huazhong University of Science and Technology | SCR | 20/1/2020 to 25/2/2020 | 26/46 | 3/46 | 3/46 | NA | 2/26 | 1/20 |
| Wu et al. [45] | 201 | Wuhan, Jinyintan Hospital | SCR | 25/12/2019 to 26/1/2020 | 62/201 | 44/201 | 50/84 | 12/117 | 23/62 | 21/139 |
| Lian et al. [46] | 788 | Zhejiang | MCR | 17/1/2020 to 12/2/2020 | 100/788 | 0/788 | NA | NA | NA | NA |
Abbreviations: CFR, case fatality rate; CS, corticosteroid; MCR, multicentre retrospective study; NA, not available; SCR, single-centre retrospective study.